Immunome, Inc. (NASDAQ:IMNM) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 191,600 shares, a drop of 19.0% from the March 31st total of 236,400 shares. Approximately 2.4% of the shares of the company are sold short. Based on an average trading volume of 280,700 shares, the days-to-cover ratio is presently 0.7 days.
Shares of NASDAQ IMNM traded down $0.64 during trading on Tuesday, reaching $24.42. 69,754 shares of the company traded hands, compared to its average volume of 243,311. The firm has a 50 day simple moving average of $30.08 and a 200-day simple moving average of $20.04. Immunome has a 52-week low of $9.27 and a 52-week high of $63.78.
Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Wednesday, March 24th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). As a group, equities research analysts anticipate that Immunome will post -2.32 EPS for the current fiscal year.
Separately, Zacks Investment Research raised shares of Immunome from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a report on Tuesday.
Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
Further Reading: 52 Week Highs and Lows
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.